- Home
- OMER
OMER
Omeros Corporation
as 12-17-2024 4:00pm EST
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 667.0M | IPO Year: | 2009 |
| Target Price: | $9.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.61 - $12.65 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Omeros Corporation News
OMER Breaking Stock News: Dive into OMER Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges
Business Wire
8 days ago
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
Business Wire
16 days ago
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
GuruFocus.com
25 days ago
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News
Business Wire
a month ago
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
Thomson Reuters StreetEvents
a month ago
Q3 2024 Omeros Corp Earnings Call
GuruFocus.com
a month ago
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments
Associated Press Finance
a month ago
Omeros: Q3 Earnings Snapshot
Compare OMER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.